Mapp wins fast-track status for Ebola drug; Roche builds a tower of Basel;

@FierceBiotech: RegenX IPO raises $138M, renewing hopes for a big Q4 biotech run. Article | Follow @FierceBiotech

@JohnCFierce: Allergan and Richter win FDA approval for a once-rejected schizophrenia pill. News | Follow @JohnCFierce

> Mapp Biopharmaceutical secured the FDA's fast-track status for ZMapp, its in-development treatment for Ebola virus. News

> Aduro Biotech ($ADRO) has leased a 56,000-square-foot space in Berkeley to house its R&D efforts as it moves forward with a pipeline of immuno-oncology treatments. Story

> Roche ($RHHBY) has constructed a 41-story skyscraper in its native Basel, a move that "can be seen as a defiant reaction to the arrival of others moving into a space Roche has dominated for the last 15 years," an analyst told Reuters. More

Medical Device News

@FierceMedDev: ICYMI yesterday: U.K. scientists develop ultrasonic device to better clean medical instruments. Article | Follow @FierceMedDev

@EmilyWFierce: Jaychem Industries is feeling the burn from an FDA warning letter over its GolfersSkin Sunscreen. FiercePharmaManufacturing story | Follow @EmilyWFierce

> Penumbra goes public in upsized $120M deal, med tech's largest IPO of 2015. Story

> Upstart Establishment gets $20M+ to bring safer breast implants with nanotech, RFID tracking to U.S. Article

> FDA cautions against improperly cleaned bronchoscope devices. More

Pharma News

@FiercePharma: India's Sun Pharma makes $48M purchase of eyecare firm InSite Vision. FiercePharmaAsia item | Follow @FiercePharma

@EricPFierce: Ireland pharma biz going to the dogs, so to speak. Nextvet picks up biologics plant there. FiercePharmaManufacturing item | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Perrigo officially rejects Mylan's 'insulting,' 'ego'-driven buyout offer. Item | Follow @CarlyHFierce

> Perrigo CEO has slammed Mylan for months--but he owns its shares. More

> FDA asks Pfizer for Zoloft label update highlighting birth defect risks. Story

> Allergan and Richter's antipsychotic gets FDA OK but faces stiff competition. Article

Suggested Articles

Horizon Therapeutics is expanding its U.S. footprint to the Bay Area—the company unveiled a new R&D and manufacturing site in South San Francisco.

Azeria Therapeutics has raised £32 million ($41 million) to take its estrogen receptor positive breast cancer program into the clinic.

Biogen’s Al Sandrock has given a bullish assessment of Alzheimer’s disease drug aducanumab. The head of R&D at Biogen thinks the drug works, despite i